Conantokin RAlternative Names: Con R
Latest Information Update: 04 Dec 2003
At a glance
- Originator Cognetix
- Mechanism of Action NMDA receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Seizures
Most Recent Events
- 04 Dec 2003 No development reported - Preclinical for Seizures in USA (unspecified route)
- 23 Feb 2000 New profile
- 23 Feb 2000 Preclinical development for Seizures in USA (Unknown route)